A peptide-based pH-sensitive drug delivery system for targeted ablation of cancer cells

Area of Science:

• Biomedical Engineering
• Oncology
• Drug Delivery Systems

Background:

• Doxorubicin is a potent chemotherapy agent with significant systemic toxicity.
• Targeted drug delivery aims to improve therapeutic efficacy and reduce side effects.
• Tumor microenvironments often exhibit lower pH, presenting an opportunity for targeted drug release.

Purpose of the Study:

• To develop a peptide-guided prodrug for targeted cancer therapy.
• To incorporate doxorubicin and a pH-sensitive linker for controlled drug release.
• To evaluate the efficacy and safety of the prodrug in cancer cell ablation.

Main Methods:

• Synthesis of a prodrug conjugate linking a tumor-specific peptide, doxorubicin, and a pH-sensitive hydrazone bridge.
• In vitro evaluation of prodrug stability and drug release at different pH values.
• Assessment of cancer cell uptake, cytotoxicity, and targeted ablation using the developed prodrug.

Main Results:

• The peptide-guided prodrug successfully targeted cancer cells.
• The pH-sensitive hydrazone bridge facilitated doxorubicin release in acidic tumor environments.
• Significant cancer cell ablation was observed with reduced cytotoxicity compared to free doxorubicin.

Conclusions:

• Peptide-guided prodrugs offer a promising strategy for targeted cancer therapy.
• pH-sensitive linkers enhance the specificity of drug release at the tumor site.
• This approach holds potential for improving cancer treatment outcomes by maximizing efficacy and minimizing side effects.